• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

6 岁男孩志贺毒素相关性溶血尿毒综合征中 CFH 和 CFB 突变。

CFH and CFB mutations in Shiga toxin-associated haemolytic uraemic syndrome in a 6-year-old boy.

机构信息

Department of Pediatric Nephrology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.

出版信息

Paediatr Int Child Health. 2020 May;40(2):129-131. doi: 10.1080/20469047.2019.1616458. Epub 2019 Jun 27.

DOI:10.1080/20469047.2019.1616458
PMID:31242818
Abstract

Haemolytic uraemic syndrome (HUS) is most commonly associated with Shiga toxin-producing (STEC) while the recurrent hereditary atypical (aHUS) form secondary to complement system control protein mutations is relatively rare. A 6-year-old boy with complement factor H (CFH) and factor B (CFB) mutations and a history of bloody diarrhoea and PCR positivity for Shiga toxin was initially diagnosed as STEC+HUS. Acute kidney injury resolved with Eculizumab but he remains with chronic renal failure. Although the exact role of STEC in the pathogenesis of aHUS in this patient is not certain, there seems to be a relationship. However, several issues remain to be explained including the effect of genetic and environmental factors in modifying susceptibility to develop aHUS in some patients following STEC infection.: aHUS: atypical haemolytic uraemic syndrome; ANA: anti-nuclear antibody; ANCA: anti-neutrophil cytoplasmic antibody; ASO: anti-streptolysin O; BUN: blood urea nitrogen; CFB: complement factor B; CFH: complement factor H; EHEC: enterohaemorrhagic ; MCP: membrane co-factor protein; PD: peritoneal dialysis; STEC: Shiga toxin-producing ; STX 1-2: Shiga toxins 1-2.

摘要

溶血尿毒综合征(HUS)最常与产志贺样毒素(STEC)相关,而继发于补体系统控制蛋白突变的复发性遗传性非典型(aHUS)形式则相对较少见。一名 6 岁男孩存在补体因子 H(CFH)和补体因子 B(CFB)突变,并有血便和志贺毒素 PCR 阳性的病史,最初被诊断为 STEC+HUS。依库珠单抗治疗后急性肾损伤得到缓解,但仍存在慢性肾衰竭。尽管 STEC 在该患者的 aHUS 发病机制中的确切作用尚不确定,但似乎存在关联。然而,仍有一些问题需要解释,包括遗传和环境因素在某些患者继发于 STEC 感染后发生 aHUS 中的作用:aHUS:非典型溶血尿毒综合征;ANA:抗核抗体;ANCA:抗中性粒细胞胞质抗体;ASO:抗链球菌溶血素 O;BUN:血尿素氮;CFB:补体因子 B;CFH:补体因子 H;EHEC:肠出血性大肠埃希菌;MCP:膜辅因子蛋白;PD:腹膜透析;STEC:产志贺样毒素;STX1-2:志贺毒素 1-2。

相似文献

1
CFH and CFB mutations in Shiga toxin-associated haemolytic uraemic syndrome in a 6-year-old boy.6 岁男孩志贺毒素相关性溶血尿毒综合征中 CFH 和 CFB 突变。
Paediatr Int Child Health. 2020 May;40(2):129-131. doi: 10.1080/20469047.2019.1616458. Epub 2019 Jun 27.
2
CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).一例志贺毒素相关性溶血尿毒综合征(STEC-HUS)中的CFH基因突变
Pediatr Nephrol. 2016 Jan;31(1):157-61. doi: 10.1007/s00467-015-3207-2. Epub 2015 Sep 23.
3
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.依库珠单抗治疗志贺毒素溶血尿毒综合征。
Pediatr Nephrol. 2019 Sep;34(9):1485-1492. doi: 10.1007/s00467-018-4025-0. Epub 2018 Jul 30.
4
Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.感染诱导及补体介导的溶血性尿毒症综合征中的血清学及基因补体改变
Pediatr Nephrol. 2017 Feb;32(2):297-309. doi: 10.1007/s00467-016-3496-0. Epub 2016 Oct 7.
5
Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland.波兰溶血尿毒综合征患儿对产志贺毒素大肠杆菌(STEC)脂多糖和重组蛋白的抗体反应。
Lett Appl Microbiol. 2020 Jun;70(6):440-446. doi: 10.1111/lam.13295. Epub 2020 Apr 28.
6
Novel Complement Factor B Gene Mutation Identified in a Kidney Transplant Recipient with a Shiga Toxin-Triggered Episode of Thrombotic Microangiopathy.在一名因志贺毒素触发的血栓性微血管病而接受肾移植的患者中发现新型补体因子 B 基因突变。
Am J Case Rep. 2022 Oct 28;23:e936565. doi: 10.12659/AJCR.936565.
7
HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.一名 4 岁女孩因 CFH 和产志贺毒素大肠杆菌感染的 HUS 接受依库珠单抗治疗。
Pediatr Nephrol. 2023 Apr;38(4):1195-1203. doi: 10.1007/s00467-022-05694-z. Epub 2022 Aug 15.
8
Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.舒巴坦酶相关溶血尿毒综合征患儿接受依库珠单抗治疗的结局:一项匹配队列研究。
Nephrol Dial Transplant. 2020 Dec 4;35(12):2147-2153. doi: 10.1093/ndt/gfz158.
9
[Complement factor B mutation in atypical hemolytic uremic syndrome. Rare cause of rare disease].[非典型溶血性尿毒症综合征中的补体因子B突变。罕见疾病的罕见病因]
G Ital Nefrol. 2017 Apr;34(2):74-81.
10
Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview.志贺毒素引起的溶血尿毒综合征和抗生素的作用:全球概述。
J Infect. 2019 Aug;79(2):75-94. doi: 10.1016/j.jinf.2019.05.018. Epub 2019 May 28.

引用本文的文献

1
Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome.产志贺毒素大肠杆菌感染作为非典型溶血尿毒综合征的诱发因素。
Pediatr Nephrol. 2025 Feb;40(2):449-461. doi: 10.1007/s00467-024-06480-9. Epub 2024 Sep 30.
2
Constipation and hemolytic uremic syndrome.便秘和溶血尿毒综合征。
Pediatr Nephrol. 2024 Feb;39(2):603-607. doi: 10.1007/s00467-023-06093-8. Epub 2023 Jul 20.
3
Thrombotic microangiopathy in children.儿童血栓性微血管病。
Pediatr Nephrol. 2022 Sep;37(9):1967-1980. doi: 10.1007/s00467-021-05370-8. Epub 2022 Jan 18.
4
Complement in Secondary Thrombotic Microangiopathy.继发性血栓性微血管病中的补体
Kidney Int Rep. 2021 Jan;6(1):11-23. doi: 10.1016/j.ekir.2020.10.009. Epub 2020 Oct 21.